Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, current …

The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood
pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential …

The renin–angiotensin system (RAS) is a key component of cardiovascular physiology and
homeostasis due to its influence on the regulation of electrolyte balance, blood pressure …

The renin-angiotensin system (RAS) plays a major role in the pathophysiology of
cardiovascular disorders. Angiotensin II (Ang-II), the final product of this pathway, is known …

Hyperactivity of the renin–angiotensin–aldosterone system through the angiotensin II (Ang
II)/Ang II type 1 receptor (AT1-R) axis constitutes a hallmark of hypertension. Recent findings …

Hypertension afflicts over 65 million Americans and poses an increased risk for
cardiovascular morbidity such as stroke, myocardial infarction and end-stage renal disease …

Since the initial description of angiotensin II–mediated hypertension 40 years ago, basic and
clinical investigations of the renin-angiotensin system (RAS) have resulted in a broader …

A large body of evidence implicates the renin–angiotensin system in the pathogenesis of
cardiovascular disease. However, not everyone understands that the magnitude of the risk …

Angiotensin receptor blockers (ARBs) are well-tolerated drugs that are known to be useful
for inhibiting activity of the renin–angiotensin (RAS) system, treating hypertension and …

Despite the tremendous success obtained using the current pharmacotherapy, especially
angiotensin (Ang)-converting enzyme (ACE) inhibitors (ACEis) and Ang II receptor blockers …